secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001193125-25-056708
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01, 5.03
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience relaunches as Whitehawk Therapeutics; reports FY2024 net loss $63.7M, $100M PIPE closed
--------------------------------------------------------------------------------

- Name changed to Whitehawk Therapeutics; stock begins trading under 'WHWK' on Nasdaq effective March 19, 2025.
- Closed $100M PIPE financing; pending divestiture of FYARRO business to Kaken Pharmaceuticals.
- Cash position $47.2M at Dec 31, 2024; expected $170-180M after transactions, funding operations into 2028.
- FY2024 total revenue $26.0M from FYARRO; net loss $63.7M vs $65.8M in 2023.
- ADC portfolio: three assets targeting PTK7, MUC16, SEZ6; goal to bring all to IND within 15 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312525056708/0001193125-25-056708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312525056708/d839636d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-056708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer